Business Context and Reporting Period
Company: Coeptis Therapeutics Holdings, Inc. (Ticker: COEP)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Coeptis is a biopharmaceutical and technology holding company. The biopharmaceutical division develops cell therapy platforms for cancer, autoimmune, and infectious diseases (including SNAP-CAR and GEAR technologies). The technology division, NexGenAI, provides AI-powered marketing software and robotic process automation. The company is an Emerging Growth Company and a Smaller Reporting Company.
Corporate Structure: The company operates through subsidiaries including SNAP Biosciences, Inc., GEAR Therapeutics, Inc., and Coeptis Therapeutics, Inc. A pending merger with Z Squared, Inc. is expected to close in Q2 2026, involving a spin-out of biotechnology operations.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $1,363,045 | $0 |
| Gross Profit | $1,182,420 | $0 |
| Net Loss | $(12,277,192) | $(10,877,412) |
| Accumulated Deficit | $(109,953,728) | $(98,036,713) |
| Cash and Cash Equivalents | $5,674,302 | $532,885 |
| Total Assets | $16,153,921 | $8,908,660 |
| Total Liabilities | $2,085,764 | $5,041,434 |
| Stockholders' Equity | $14,068,157 | $3,867,226 |
Operating Expenses: Total operating expenses increased to $14,225,918 in 2025 from $10,054,488 in 2024. This increase was driven by higher professional services fees (related to the pending merger) and stock-based compensation. Research and development expenses decreased to $1,277,150 from $2,331,548, largely due to the termination of the Shared Services Agreement with Deverra Therapeutics.
Liquidity: Cash increased significantly from $532,885 to $5,674,302, primarily due to private placement common stock offerings and draws under a Standby Equity Purchase Agreement (SEPA).
Material Changes vs. Prior Period
- Revenue Generation: The company generated $1.36 million in revenue in 2025, a shift from zero revenue in 2024. This revenue stems from the NexGenAI technology segment (lead generation and webinar services).
- Loss Expansion: Net loss increased by approximately $1.4 million year-over-year, despite revenue generation, due to elevated operating costs and amortization of debt discounts.
- Capital Structure: The company completed a $10 million Series A preferred stock offering in 2025, all of which was converted to common stock. Additionally, the company raised funds through private placements and the SEPA.
- Derivative Liabilities: The company recognized a gain of $1,098,055 on the change in fair value of derivative liabilities in 2025, compared to a loss of $341,660 in 2024. The SEPA derivative liability was extinguished in 2025.
- Going Concern: The independent auditor's report includes an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern, citing the need for additional capital to fund operations and service indebtedness.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: Management anticipates continuing operating losses and negative cash flow from operations. The company plans to raise additional capital through equity or debt transactions to fund its business plan. The pending merger with Z Squared, Inc. is expected to close in Q2 2026, which will involve spinning out biotechnology operations.
Risks:
- Going Concern: Substantial doubt exists regarding the ability to continue operations without additional financing.
- Regulatory Approval: Product candidates are in pre-clinical or early clinical stages; there is no assurance of FDA approval or commercial success.
- Market Volatility: The company faced Nasdaq listing compliance issues regarding minimum bid price in 2024 but regained compliance in 2025. A subsequent notice in Jan 2026 regarding failure to hold an annual meeting was resolved in Feb 2026.
- Intellectual Property: The company relies on third-party licenses (e.g., University of Pittsburgh, Deverra, Vy-Gen) and faces risks related to patent protection and enforcement.
Unusual Items:
- Non-Cash Gains: Significant non-cash gains were recorded from the change in fair value of derivative liabilities ($1.1M) and unrealized gains on marketable securities ($76,596).
- Asset Acquisitions: The company acquired NexGenAI assets in late 2024, contributing to the new revenue stream.
Investor Verification Checklist
- Capital Adequacy: Verify the company's ability to secure additional financing given the "substantial doubt" going concern qualification and the high burn rate relative to cash on hand.
- Merger Status: Confirm the progress and terms of the pending merger with Z Squared, Inc., specifically the mechanics of the biotechnology spin-out and the expected closing date (Q2 2026).
- Revenue Sustainability: Assess the sustainability of the $1.36M revenue from the NexGenAI segment and whether it can scale to offset biopharmaceutical R&D costs.
- Derivative Accounting: Review the valuation assumptions for derivative liabilities (SEPA and warrants) which significantly impacted net income through non-cash gains/losses.
- Stock Dilution: Monitor the impact of the SEPA and recent private placements on share count and potential dilution to existing shareholders.
- Nasdaq Compliance: Ensure the company maintains compliance with Nasdaq listing requirements, particularly regarding minimum bid price and shareholder meeting protocols.